Cargando…
ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants
Although the antibody response to COVID-19 vaccination has been studied extensively at the polyclonal level using immune sera, little has been reported on the antibody response at the monoclonal level. Here, we isolate a panel of 44 anti-SARS-CoV-2 monoclonal antibodies (mAbs) from an individual who...
Autores principales: | Seow, Jeffrey, Graham, Carl, Hallett, Sadie R., Lechmere, Thomas, Maguire, Thomas J.A., Huettner, Isabella, Cox, Daniel, Khan, Hataf, Pickering, Suzanne, Roberts, Rebekah, Waters, Anele, Ward, Christopher C., Mant, Christine, Pitcher, Michael J., Spencer, Jo, Fox, Julie, Malim, Michael H., Doores, Katie J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cell Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010245/ https://www.ncbi.nlm.nih.gov/pubmed/35477023 http://dx.doi.org/10.1016/j.celrep.2022.110757 |
Ejemplares similares
-
BNT162b2 COVID-19 and ChAdOx1 nCoV-19 vaccination in patients with myelodysplastic syndromes
por: Abdul-Jawad, Sultan, et al.
Publicado: (2022) -
ChAdOx1 nCoV-19 vaccine for SARS-CoV-2
por: Lodge, Archie
Publicado: (2020) -
ChAdOx1 nCoV-19 vaccine for SARS-CoV-2
por: Chauhan, Anil, et al.
Publicado: (2020) -
The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern
por: Graham, Carl, et al.
Publicado: (2022) -
ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 – Authors' reply
por: Voysey, Merryn, et al.
Publicado: (2020)